Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Updated results from TIGER-X, a phase open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). Goldman, J., Soria, J., Wakelee, H. A., Camidge, D., Gadgeel, S. M., Yu, H., Reckamp, K. L., Papadimitrakopoulou, V., Perol, M., Ou, S., Matheny, S. L., Despain, D., Isaacson, J. D., Yurasov, S., Rolfe, L., Sequis, L. V. AMER SOC CLINICAL ONCOLOGY. 2016
View details for DOI 10.1200/JCO.2016.34.15_suppl.9045
View details for Web of Science ID 000404711506193